FDA tentatively approves first generic twice-yearly HIV prevention shot
publishers 24articles 27first reported 2 Nov, 14:45 UTCdeveloping since 2 Nov · 14 editions
The U.S. Food and Drug Administration has granted tentative approval to the first generic version of lenacapavir, a twice-yearly injectable medicine used to prevent HIV.
The generic was developed by India’s Dr. Reddy’s Laboratories under a voluntary licence from Gilead Sciences, which developed the original drug. The FDA decision was announced Monday by Dr. Reddy’s and global health initiative Unitaid.
Under a pricing agreement involving Unitaid, the Clinton Health Access Initiative and African research institute Wits RHI, the generic is expected to cost $40 per person annually and be offered in 120 low- and middle-income countries. The Independent reported that Zambia is expected to receive the first supplies.
Gilead’s version was approved by the FDA in June 2025 after clinical trials found it more than 99.9% effective at preventing HIV. It costs about $28,000 annually in the United States before insurance, according to reports. Unlike a vaccine, lenacapavir does not train the immune system; it is a form of pre-exposure prophylaxis that targets the protective shell around HIV’s genetic material.
Tentative FDA approval allows the generic to move closer to distribution through an accelerated pathway that relies partly on existing clinical data. Unitaid said more than 125,000 people in 10 early-adopter African countries have already begun receiving Gilead’s version.
HOW THIS STORY WAS MADE
Written from 8 articles, 2 with the publisher's own text; 7 independent newsrooms once syndicated copies count as one; this version written 24 h after the record first saw the story; the editor kept it as written.
- Publishers
- 24
- Source articles
- 27
- Given to the writer
- 8, 2 with the article's own text
- Independent newsrooms
- 7
- This version written
- 24 h after the record first saw the story
- Second model (editor)
- kept as written
- Publication gate
- passed
- Human review
- none
WHAT THE EDITOR DID
The second model checked the writer's draft against the same sources and published it as written.
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →